Onivyde is administered intravenously, typically in combination with other chemotherapy agents like fluorouracil and leucovorin. The liposomal formulation is designed to be stable in the bloodstream until it reaches the tumor site, where it releases the active drug. This targeted approach helps to maximize the drug's efficacy while minimizing systemic exposure.
